In a significant milestone for cancer therapeutics, Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company committed to addressing critical unmet medical needs, has announced the successful dosing of its first patient with a groundbreaking novel therapeutic radiopharmaceutical, MNPR-101-Lu. This development marks a pivotal advance in the company’s mission to combat some of the most aggressive forms of cancer.Dosed on December 5, 2024, MNPR-101-Lu represents a cutting-edge combination of Monopar’s proprietary antibody MNPR-101, which selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. The uPAR biomarker is intri...
Innovative Hope: Monopar Therapeutics Launches Pioneering Clinical Trial for uPAR-Targeted Radiopharmaceutical in Advanced Cancers In the ever-evolving landscape of oncology, the dawn of innovative treatments often heralds new hope for patients grappling with advanced cancers. This October, Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical pioneer, has announced a significant advancement in its clinical development pipeline: the initiation of a Phase 1a clinical trial for its groundbreaking therapeutic radiopharmaceutical, MNPR-101-Lu. This novel compound an ingenious conjugation of MNPR-101 with lutetium-177 aims to redefine treatment modalities for individuals facing advanced m...
Monopar Therapeutics Presenting Groundbreaking Data on uPAR Radiopharma Cancer Target at 2024 SNMMI Annual MeetingMonopar Therapeutics Inc. is making waves in the radiopharmaceutical industry with the presentation of data on its lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The company, focused on developing innovative treatments for cancer patients, is showcasing the appeal of uPAR as a radiopharma cancer target through its preclinical development efforts.The SNMMI Annual Meeting, known as the premier event in the radiopharma space, provides a platform for companies like Monopar to share their latest findings and advancements. The ...
WILMETTE, Ill., April 10, 2024 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a specialized clinical-stage biopharmaceutical company committed to obtaining breakthroughs in cancer treatment, has set in motion its Phase 1 dosimetry clinical trial for the innovative radiopharmaceutical imaging agent known as MNPR-101-Zr. The drug, currently under evaluation, is being introduced to patients affected with various advanced stages of cancer, followed by a recruitment process to involve more participants.MNPR-101-Zr is an amalgamation of the monoclonal antibody MNPR-101 and zirconium-89. This combined therapeutic approach emerges as an innovative move in the field of oncology, offering a promising potential for myriad...
Sources:
Monopar Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Monopar Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Monopar Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
